The current role of chemotherapy in metastatic hormone-refractory prostate cancer
- 1 May 2005
- Vol. 65 (5) , 3-7
- https://doi.org/10.1016/j.urology.2005.03.053
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate CancerJournal of Urology, 2002
- Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancerAnnals of Oncology, 2001
- Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostateSeminars in Oncology, 2001
- Weekly 1-hour infusion of paclitaxelCancer, 2000
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1996
- Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology groupCancer, 1993
- Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerCancer, 1993